Background:
The current prospective, randomized, controlled REVERSE-FLOW trial aims to systematically examine the effect of the
glycoprotein (GP) IIb/IIIa inhibitors on infarct size in patients with STEMI and NSTEMI and angiographic evidence of
no-reflow.
Trial Registration No:
SNCTP000003611
Trial Status:
active
Enrolling Centers:
5
Core Study Team:
The current prospective, randomized, controlled REVERSE-FLOW trial aims to systematically examine the effect of the
glycoprotein (GP) IIb/IIIa inhibitors on infarct size in patients with STEMI and NSTEMI and angiographic evidence of
no-reflow.
Trial Registration No:
SNCTP000003611
Trial Status:
active
Enrolling Centers:
5
Core Study Team:
© Christian Mueller, 2012 - 2020 │ Disclaimer │ Imprint │ Webmaster │ Last Update: Mai 2020
